Genetic Variants and Tamoxifen Response in Breast Cancer
Author Information
Author(s): Pia Wegman, Sauli Elingarami, John Carstensen, Olle Stål, Bo Nordenskjöld, Sten Wingren
Primary Institution: Linköping University
Hypothesis
Can genetic polymorphisms in CYP3A5, CYP2D6, SULT1A1, and UGT2B15 predict the response to tamoxifen therapy in postmenopausal breast cancer patients?
Conclusion
Genetic variation in CYP3A5 may predict response to tamoxifen therapy, but the metabolism of tamoxifen is complex and influenced by multiple factors.
Supporting Evidence
- Patients homozygous for CYP2D6*4 had significantly better disease-free survival.
- CYP3A5*3 homozygous patients showed improved recurrence-free survival with 5 years of tamoxifen.
- No significant differences were observed for CYP2D6, SULT1A1, and UGT2B15 genotypes.
Takeaway
Some people have different genes that can affect how well tamoxifen works for them in treating breast cancer.
Methodology
677 postmenopausal breast cancer patients were genotyped for specific polymorphisms and their response to tamoxifen was analyzed.
Potential Biases
Potential misclassification of genotypes due to tumor heterogeneity.
Limitations
The study only analyzed tumor DNA, which may introduce risks of genotype misclassification.
Participant Demographics
Postmenopausal women aged 50 to 96, mean age 69, diagnosed with stage II and III breast cancer.
Statistical Information
P-Value
0.002
Confidence Interval
0.07 to 0.55
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website